New injection shows promise for kidney disease in early trial
NCT ID NCT07289763
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a new drug, SHR-2173, in 75 adults with primary membranous nephropathy, a kidney disease. The goal is to see if the drug is safe and can help control the disease by reducing protein in the urine. Participants will receive the drug and be monitored for side effects and kidney function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General hospital of eastern theater command
RECRUITINGNanjing, Jiangsu, 210002, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.